Countless adults struggle with restless nights, turning to an array of alternative treatments in search of relief. Millions of people regularly reach for cannabis to combat sleeplessness, yet a sweeping new review published this week reveals a striking lack of solid scientific data backing up its effectiveness.
Researchers with the Cochrane Library conducted an extensive analysis of randomized clinical trials examining medical-grade cannabis for insomnia. Investigators evaluated nine distinct studies involving a total of 537 participants ranging in age from 18 to 76. The majority of these individuals suffered from primary insomnia, meaning sleep difficulties unlinked to underlying medical conditions. Most of the trials compared medical cannabis directly against a placebo, while one study utilized an antidepressant for comparison.
The findings indicate that cannabis failed to demonstrate clear superiority over control treatments across standard sleep metrics. Investigators found no reliable evidence of clinically meaningful improvements in overall sleep quality, total sleep duration, or daytime alertness. Additionally, mild adverse events such as dizziness and dry mouth occurred more frequently among participants who consumed medical cannabis, though data regarding long-term safety remains sparse.
Lead author Lucia Varela, a neurologist and fellow at the University of Manitoba, emphasized that the results do not definitively prove the treatment is useless. Instead, the available clinical literature suffers from small sample sizes, short observation periods—with the longest following patients for only 12 weeks—and a high risk of bias. Experts stress that patients should consult healthcare providers rather than assume commercial products are proven sleep aids.
Medical Cannabis Lacks Solid Evidence for Treating Insomnia, Review Finds
Comments